Skip Nav Destination
Issues
1 January 2005
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorial
The Biology Behind
Report from the Food and Drug Administration
Human Cancer Biology
Inhibitory Effect of Antagonists of Bombesin and Growth Hormone-Releasing Hormone on Orthotopic and Intraosseous Growth and Invasiveness of PC-3 Human Prostate Cancer in Nude Mice
Anton Stangelberger; Andrew V. Schally; Jozsef L. Varga; Marta Zarandi; Karoly Szepeshazi; Patricia Armatis; Gabor Halmos
Vaccination of Dendritic Cells Loaded with Interleukin-12-Secreting Cancer Cells Augments In vivo Antitumor Immunity: Characteristics of Syngeneic and Allogeneic Antigen-Presenting Cell Cancer Hybrid Cells
Takuji Suzuki; Tatsuro Fukuhara; Masashi Tanaka; Akira Nakamura; Kenichi Akiyama; Tomohiro Sakakibara; Daizo Koinuma; Toshiaki Kikuchi; Ryushi Tazawa; Makoto Maemondo; Koichi Hagiwara; Yasuo Saijo; Toshihiro Nukiwa
Colocalization of Carbonic Anhydrase 9 Expression and Cell Proliferation in Human Head and Neck Squamous Cell Carcinoma
Ilse J. Hoogsteen; Henri A.M. Marres; Karien I.E.M. Wijffels; Paul F.J.W. Rijken; Johannes P.W. Peters; Franciscus J.A. van den Hoogen; Egbert Oosterwijk; Albert J. van der Kogel; Johannes H.A.M. Kaanders
Imaging, Diagnosis, Prognosis
Prognostic Relevance of Fragile Histidine Triad Protein Expression in Patients with Small Cell Lung Cancer
Ulrich-Peter Rohr; Nina Rehfeld; Helene Geddert; Lucy Pflugfelder; Ingmar Bruns; Judith Neukirch; Astrid Rohrbeck; Hans J. Grote; Ulrich Steidl; Roland Fenk; Bertram Opalka; Helmut E. Gabbert; Ralf Kronenwett; Rainer Haas
A Robust Assay for Alternative Lengthening of Telomeres in Tumors Shows the Significance of Alternative Lengthening of Telomeres in Sarcomas and Astrocytomas
Jeremy D. Henson; Jonathan A. Hannay; Stanley W. McCarthy; Janice A. Royds; Thomas R. Yeager; Robert A. Robinson; Stephen B. Wharton; David A. Jellinek; Susan M. Arbuckle; Jinyoung Yoo; Bruce G. Robinson; Diana L. Learoyd; Paul D. Stalley; S. Fiona Bonar; Dihua Yu; Raphael E. Pollock; Roger R. Reddel
Expression of EphA2 is Prognostic of Disease-Free Interval and Overall Survival in Surgically Treated Patients with Renal Cell Carcinoma
Christopher J. Herrem; Tomohide Tatsumi; Kathleen S. Olson; Keisuke Shirai; James H. Finke; Ronald M. Bukowski; Ming Zhou; Amy L. Richmond; Ithaar Derweesh; Michael S. Kinch; Walter J. Storkus
Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non–Small Cell Lung Carcinoma
Louise Burke; Douglas B. Flieder; Donald G. Guinee; Elizabeth Brambilla; Andrew N. Freedman; William P. Bennett; Raymond T. Jones; Andrew Borkowski; Neil A. Caporaso; Marian Fleming; Victor Trastek; Peter Pairolero; Henry Tazelaar; David Midthun; James R. Jett; Lance A. Liotta; William D. Travis; Curtis C. Harris
Minichromosome Maintenance Protein 3 Elicits a Cancer-Restricted Immune Response in Patients with Brain Malignancies and Is a Strong Independent Predictor of Survival in Patients with Anaplastic Astrocytoma
Ariane Söling; Mirko Sackewitz; Michael Volkmar; Daniel Schaarschmidt; Roland Jacob; Hans-Jürgen Holzhausen; Nikolai G. Rainov
Cancer Therapy: Clinical
Addition of Histamine to Interleukin 2 Treatment Augments Type 1 T-Cell Responses in Patients with Melanoma In vivo: Immunologic Results from a Randomized Clinical Trial of Interleukin 2 with or without Histamine (MP 104)
Anne Marie Asemissen; Carmen Scheibenbogen; Anne Letsch; Kristoffer Hellstrand; Fredrik Thorén; Kurt Gehlsen; Alexander Schmittel; Eckhard Thiel; Ulrich Keilholz
Class III β-Tubulin Overexpression Is a Prominent Mechanism of Paclitaxel Resistance in Ovarian Cancer Patients
Simona Mozzetti; Cristiano Ferlini; Paola Concolino; Flavia Filippetti; Giuseppina Raspaglio; Silvia Prislei; Daniela Gallo; Enrica Martinelli; Franco Oreste Ranelletti; Gabriella Ferrandina; Giovanni Scambia
Cancer Therapy: Preclinical
TAS-108, a Novel Oral Steroidal Antiestrogenic Agent, Is a Pure Antagonist on Estrogen Receptor α and a Partial Agonist on Estrogen Receptor β with Low Uterotrophic Effect
Yasuji Yamamoto; Jiro Shibata; Kazuhiko Yonekura; Kouji Sato; Akihiro Hashimoto; Yoshimi Aoyagi; Konstanty Wierzba; Shingo Yano; Tetsuji Asao; Aman U. Buzdar; Tadafumi Terada
Clinical and Molecular Evidence for c-kit Receptor as a Therapeutic Target in Neuroblastic Tumors
Stefania Uccini; Olga Mannarino; Heather P. McDowell; Ursula Pauser; Roberta Vitali; Pier Giorgio Natali; Pierluigi Altavista; Tiziana Andreano; Simona Coco; Renata Boldrini; Sandro Bosco; Anna Clerico; Denis Cozzi; Alberto Donfrancesco; Alessandro Inserra; George Kokai; Paul D. Losty; Maria R. Nicotra; Giuseppe Raschellà; Gian Paolo Tonini; Carlo Dominici
Letters to the Editor
Anti-Vascular Endothelial Growth Factor Receptor-2 Antibody Accelerates Renal Disease in the NZB/W F1 Murine Systemic Lupus Erythematosus Model
Hideaki Watanabe; Adam J. Mamelak; Elliot Weiss; Binghe Wang; Irwin Freed; Angela K. Brice; Lynn Wachtman; Kathleen L. Gabrielson; Naoko Yokota; Daniel J. Hicklin; Robert S. Kerbel; Mark Haas; Daniel N. Sauder
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.